Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Front Pharmacol · 2018 · PMC5958190 · PMID 29867488

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

fell short of significanceno p-value reported

In accordance, in one recent clinical trial using CBD as an adjunctive therapy for schizophrenia, CBD group displayed greater cognitive improvement (assessed by BACS—Brief Assessment of Cognition in Schizophrenia), although it fell short of significance (McGuire et al., 2018 ).

also in 361 other papers

showed a trendno p-value reported

In a hamster model of idiopathic paroxysmal dystonia, the higher dose of CBD showed a trend to delay the progression of dystonia (Richter and Loscher, 2002 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.